EPRX - Eupraxia Pharmaceuticals Inc. News

Sectors

EPRX

Eupraxia Pharmaceuticals Inc.

6.82

1 x 5.72

15 x 7.56

bid

ask

0.10

1.49%

1 @ 04:00 PM

7.56 +0.74 (10.85%)

Ytd	-9.67%
1y	28.20%

6.65

day range

6.85

5.04

52 week range

9.32

Open	6.80	Prev Close	6.72	Low	6.65	High	6.85	Mkt Cap	228.33M
Vol	126.13K	Avg Vol	363.31K	EPS	-1.05	P/E	-6.50	Forward P/E	N/A
Beta	1.23	Short Ratio	27.74	Inst. Own	12.85%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-11	50-d Avg	6.41	200-d Avg	7.05	1yr Est	0.00

EPRX News

globenewswire.com

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, I

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts

globenewswire.com

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflamm

zacks.com

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Rea

The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPR

defenseworld.net

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX - Get Free Report) have received an average ra

globenewswire.com

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra

globenewswire.com

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Comme

VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupra

globenewswire.com

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra

globenewswire.com

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Euprax

globenewswire.com

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Compl

globenewswire.com

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOL

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue dam

globenewswire.com

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophil

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endosc

globenewswire.com

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Euprax

globenewswire.com

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupr

zacks.com

New Strong Sell Stocks for April 2nd

ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.

benzinga.com

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinic

defenseworld.net

Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX

Ally Bridge Group NY LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) in th

globenewswire.com

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra

globenewswire.com

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercis

VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax

globenewswire.com

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre

VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax

globenewswire.com

Eupraxia Pharmaceuticals Announces Proposed Public Offering

VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market